Tumor site, age, number of hormone therapy,radiotherapy and chemotherapy sessions, and molecular markers such as estrogenreceptor, progesterone receptor, Ki-67 protein, p53, HER2 mutation and molecularsubtype were examined. The gene discussed is ERBB2; the disease is neoplasm.